T
Tetsuro Kikuchi
Researcher at Otsuka Pharmaceutical
Publications - 115
Citations - 4818
Tetsuro Kikuchi is an academic researcher from Otsuka Pharmaceutical. The author has contributed to research in topics: Dopamine receptor D2 & Aripiprazole. The author has an hindex of 31, co-authored 113 publications receiving 4553 citations. Previous affiliations of Tetsuro Kikuchi include Salisbury University.
Papers
More filters
Journal ArticleDOI
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors
Kevin D. Burris,Thaddeus F. Molski,Cen Xu,Elaine Ryan,Katsura Tottori,Tetsuro Kikuchi,Frank D. Yocca,Perry B. Molinoff +7 more
TL;DR: These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.
Journal ArticleDOI
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
TL;DR: Aripiprazole is the first dopamine-serotonin system stabilizer, according to a study demonstrating potent, partial agonism at 5-HT(1A) receptors in a guanosine-5'-O-(3-[( 35)S]thio)-triphosphate ([(35)S)GTP gamma S)-binding assay.
Journal Article
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Tetsuro Kikuchi,Katsura Tottori,Yasufumi Uwahodo,Tsuyoshi Hirose,Takashi Miwa,Yasuo Oshiro,Seiji Morita +6 more
TL;DR: The effects of 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2 (1H)- quinolinone (OPC-14597) on DA receptors were biochemically and behaviorally studied and compared with those of OPC-4392.
Journal ArticleDOI
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597): A new antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Tetsuro Kikuchi,Katsura Tottori,Yasufumi Uwahodo,Takashi Miwa,Tsuyoshi Hirose,Kiyoshi Fujiwara,Yasuo Oshiro,Seiji Morita +7 more
TL;DR: OPC-14597 is a unique antipsychotic drug candidate, being a DA autoreceptor agonist that has a stronger postsynaptic D2 receptor antagonistic activity than that of OPC-4392.
Journal ArticleDOI
Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Kenji Maeda,Haruhiko Sugino,Hitomi Akazawa,Naoki Amada,Jun Shimada,Takashi Futamura,Hiroshi Yamashita,Nobuaki Ito,Robert D. McQuade,Arne Mørk,Alan L. Pehrson,Morten Hentzer,Vibeke Nielsen,Christoffer Bundgaard,Jørn Arnt,Tine B. Stensbøl,Tetsuro Kikuchi +16 more
TL;DR: Based on a lower intrinsic activity at D2 receptors and higher binding affinities for 5-HT1A/2A receptors than aripiprazole, brexpiprazoles would have a favorable antipsychotic potential without D2 receptor agonist- and antagonist-related adverse effects.